Examkin

Soru

Zorluk: OrtaPharmacologic Interventions

A 75-year-old woman is brought to the outpatient clinic by her daughter for evaluation of bothersome urinary symptoms. Over the past three months, the patient has experienced sudden, overwhelming urges to urinate, often resulting in urinary leakage before she can reach the bathroom. She currently voids approximately 10 to 12 times a day. Her medical history is significant for Alzheimer dementia, for which she is prescribed donepezil, and essential hypertension, which is well-controlled with amlodipine. Vital signs are within normal limits. Physical examination, including a pelvic exam, is unremarkable. A bladder ultrasound reveals a post-void residual volume of 35 mL. Urinalysis shows no signs of infection. Behavioral interventions, including scheduled voiding and fluid management, were initiated four weeks ago but have been unsuccessful. Which of the following is the most appropriate medication to initiate for this patient's urinary symptoms?

  1. MirabegronCevap
  2. B
    Oxybutynin
  3. C
    Solifenacin
  4. D
    Bethanechol
  5. E
    Amitriptyline

Cevap

Mirabegron
The correct answer is mirabegron. This patient presents with overactive bladder (OAB) characterized by urge incontinence, urinary frequency, and urgency. Because behavioral interventions have failed, pharmacotherapy is indicated. The standard initial pharmacotherapies for OAB include antimuscarinic agents and beta-3 adrenergic agonists. However, this patient has Alzheimer dementia and is being treated with donepezil, an acetylcholinesterase inhibitor. Antimuscarinic drugs (especially those that cross the blood-brain barrier) can cause profound cognitive impairment in the elderly and directly antagonize the beneficial effects of acetylcholinesterase inhibitors. Mirabegron is a beta-3 adrenergic agonist that causes relaxation of the detrusor muscle during the urine storage phase. It effectively increases bladder capacity and reduces OAB symptoms without exerting any anticholinergic effects, making it the safest and most appropriate choice for this patient.

Adım Adım Çözüm

1
Identify the patient's primary clinical problem and active comorbidities.
The patient has overactive bladder (OAB) manifesting as urge incontinence, alongside a critical comorbidity of Alzheimer dementia currently treated with donepezil.
Choosing a pharmacologic intervention for OAB requires careful avoidance of drugs that could worsen the patient's underlying neurological condition or interact with her current medications.
2
Determine the standard pharmacological classes available for overactive bladder.
The two primary classes are antimuscarinic agents (e.g., oxybutynin, solifenacin) and beta-3 adrenergic agonists (e.g., mirabegron).
Since conservative behavioral management has failed, pharmacotherapy is the next step in the treatment algorithm.
3
Evaluate the safety and interaction profiles of the available classes in the context of dementia.
Antimuscarinic agents block acetylcholine receptors, which can directly cause cognitive impairment and pharmacodynamically antagonize acetylcholinesterase inhibitors like donepezil.
Medications with central anticholinergic properties must be rigorously avoided in the elderly, particularly those with established cognitive decline.
4
Select the optimal medication based on efficacy and safety.
Mirabegron is selected as the most appropriate agent.
Mirabegron stimulates beta-3 receptors in the bladder to promote detrusor relaxation during the storage phase without interfering with cholinergic transmission in the central nervous system.

Anahtar Kavram

Pharmacologic management of overactive bladder in patients with dementia
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru